Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder

Overview

Journal J Gen Intern Med

Publisher Springer

Specialty General Medicine

Date 2024 Feb 29

PMID 38424347

Authors

Jennifer K Bello

Kevin Y Xu

Joanne Salas

Bronwyn S Bedrick

Richard A Grucza

Affiliations

Soon will be listed here.

Abstract

Background: Treatment-seeking people with opioid use disorder (OUD) who are capable of pregnancy need accurate information about the potential impact of medication to treat OUD (MOUD) on fertility to make informed choices about treatment that are consistent with their reproductive wishes. There is a dearth of research on fertility associated with MOUD receipt in birthing people with OUD.

Objective: To estimate the association between treatment with MOUD and odds of conception among birthing people using national administrative claims.

Design: Retrospective case-crossover study using multi-state US administrative data (2006-2016). Dates of conception were estimated from delivery dates and served as "case" days for which MOUD exposures were compared to those on all other ("control") days of insurance enrollment.

Participants: Treatment-seeking people with OUD with a delivery during the observation period.

Main Measures: Odds ratios for conception from within-person fixed effects models were modeled as a function of exposure to MOUD (buprenorphine, methadone, extended-release depot naltrexone, or oral naltrexone) using conditional logistic regression.

Key Results: A total of 21,928 births among 19,133 people with OUD were identified. In the sample, 5873 people received buprenorphine, 1825 methadone, 486 extended-release naltrexone, and 714 oral naltrexone. Participants could receive more than one type of MOUD. Mean age was 28.2 years (SD = 2.2; range = 16-45), with 76.2% having Medicaid. vs. commercial insurance. Compared to no MOUD, periods of methadone (aOR = 0.55 [95% CI = 0.48-0.63]) or buprenorphine receipt (aOR = 0.84 [0.77-0.91]) were associated with fewer conceptions. Treatment periods with extended-release depot naltrexone compared to no medication were associated with higher odds of conception (aOR = 1.75 [1.22-2.50]) and there was no significant difference in conception with oral naltrexone (aOR = 1.02 [0.67-1.54]).

Conclusions: The association between MOUD and odds of conception among birthing people varied by type of MOUD, with extended-release naltrexone associated with higher odds of conceiving compared to no treatment. Clinical studies are urgently needed to investigate these findings further.

Citing Articles

Buprenorphine and postpartum contraception utilization among people with opioid use disorder: a multi-state analysis.

Xu K, Bello J, Buss J, Jones H, Bierut L, Stwalley D Addict Sci Clin Pract. 2025; 20(1):1.

PMID: 39762993 PMC: 11702041. DOI: 10.1186/s13722-024-00530-1.

References

Heil S, Jones H, Arria A, Kaltenbach K, Coyle M, Fischer G . Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat. 2010; 40(2):199-202. PMC: 3052960. DOI: 10.1016/j.jsat.2010.08.011. View

Fischbein R, Lanese B, Falletta L, Hamilton K, King J, Kenne D . Pregnant or recently pregnant opioid users: contraception decisions, perceptions and preferences. Contracept Reprod Med. 2018; 3:4. PMC: 5870942. DOI: 10.1186/s40834-018-0056-y. View

Collier K, MacAfee L, Kenny B, Meyer M . Does co-location of medication assisted treatment and prenatal care for women with opioid use disorder increase pregnancy planning, length of interpregnancy interval, and postpartum contraceptive uptake?. J Subst Abuse Treat. 2019; 98:73-77. DOI: 10.1016/j.jsat.2018.12.001. View

Smith C, Morse E, Busby S . Barriers to Reproductive Healthcare for Women With Opioid Use Disorder. J Perinat Neonatal Nurs. 2019; 33(2):E3-E11. DOI: 10.1097/JPN.0000000000000401. View

Daniell H . Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2007; 9(1):28-36. DOI: 10.1016/j.jpain.2007.08.005. View

Rhodin A, Stridsberg M, Gordh T . Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain. 2010; 26(5):374-80. DOI: 10.1097/AJP.0b013e3181d1059d. View

Abs R, Verhelst J, Maeyaert J, Van Buyten J, Opsomer F, Adriaensen H . Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000; 85(6):2215-22. DOI: 10.1210/jcem.85.6.6615. View

Kim C, Garcia R, Stover J, Ritchie K, Whealton T, Ata M . Androgen deficiency in long-term intrathecal opioid administration. Pain Physician. 2014; 17(4):E543-8. View

Reddy R, Aung T, Karavitaki N, Wass J . Opioid induced hypogonadism. BMJ. 2010; 341:c4462. PMC: 2974597. DOI: 10.1136/bmj.c4462. View

10.

Stowell M, Thomas-Gale T, Jones H, Binswanger I, Rinehart D . Perspectives among women receiving medications for opioid use disorder: Implications for development of a peer navigation intervention to improve access to family planning services. Subst Abus. 2022; 43(1):722-732. PMC: 9743830. DOI: 10.1080/08897077.2021.2007514. View

11.

Leridon H . Studies of fertility and fecundity: comparative approaches from demography and epidemiology. C R Biol. 2007; 330(4):339-46. DOI: 10.1016/j.crvi.2007.02.013. View

12.

Li Z, You Y, Griffin N, Feng J, Shan F . Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol. 2018; 61:178-184. DOI: 10.1016/j.intimp.2018.05.020. View

13.

Wildt L, Leyendecker G, Sir-Petermann T . Treatment with naltrexone in hypothalamic ovarian failure: induction of ovulation and pregnancy. Hum Reprod. 1993; 8(3):350-8. DOI: 10.1093/oxfordjournals.humrep.a138050. View

14.

Roozenburg B, van Dessel H, Evers J, Bots R . Successful induction of ovulation in normogonadotrophic clomiphene resistant anovulatory women by combined naltrexone and clomiphene citrate treatment. Hum Reprod. 1997; 12(8):1720-2. DOI: 10.1093/humrep/12.8.1720. View

15.

Genazzani A, Petraglia F, Gastaldi M, Volpogni C, Gamba O, Genazzani A . Naltrexone treatment restores menstrual cycles in patients with weight loss-related amenorrhea. Fertil Steril. 1995; 64(5):951-6. DOI: 10.1016/s0015-0282(16)57908-4. View

16.

Ahmed M, Duleba A, El Shahat O, Ibrahim M, Salem A . Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome. Hum Reprod. 2008; 23(11):2564-9. DOI: 10.1093/humrep/den273. View

17.

Xu K, Borodovsky J, Presnall N, Mintz C, Hartz S, Bierut L . Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis. Am J Psychiatry. 2021; 178(7):651-659. PMC: 8286284. DOI: 10.1176/appi.ajp.2020.20081174. View

18.

Saitz R, Miller S, Fiellin D, Rosenthal R . Recommended Use of Terminology in Addiction Medicine. J Addict Med. 2020; 15(1):3-7. DOI: 10.1097/ADM.0000000000000673. View

19.

Volkow N, Gordon J, Koob G . Choosing appropriate language to reduce the stigma around mental illness and substance use disorders. Neuropsychopharmacology. 2021; 46(13):2230-2232. PMC: 8580983. DOI: 10.1038/s41386-021-01069-4. View

20.

Johansson B, Berglund M, Lindgren A . Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006; 101(4):491-503. DOI: 10.1111/j.1360-0443.2006.01369.x. View